Optimising antithrombotic therapy after ACS and PCI.

Area of Science:

• Cardiology
• Pharmacology

Background:

• Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is standard for acute coronary syndrome (ACS) post-percutaneous coronary intervention (PCI).
• Optimizing DAPT requires balancing ischemic event risk against bleeding complications.

Purpose of the Study:

• To review de-escalation and escalation strategies for DAPT in ACS patients.
• To highlight the role of patient-specific risk assessment in guiding therapy.

Main Methods:

• Review of current literature on DAPT in ACS.
• Analysis of risk stratification for ischemic and bleeding events.
• Discussion of guided de-escalation and escalation protocols.

Main Results:

• De-escalation (e.g., switching to a less potent P2Y12 inhibitor) is suitable for high bleeding risk patients with low ischemic risk.
• Platelet function and genetic testing can guide de-escalation decisions.
• Escalation strategies (e.g., dose increase, adding agents) are considered for high ischemic risk patients.

Conclusions:

• Individualized DAPT strategies are crucial for ACS patients undergoing PCI.
• Risk assessment for both ischemic and bleeding complications informs treatment decisions.
• Personalized therapy, including de-escalation or escalation, optimizes outcomes.